Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28619820 | 0.89 | MAPT (0.38) | MAPTLMNATHRBTP53KDM4E | |
| SCHEMBL28618955 | 0.89 | AKR1C3 (0.37) | MAPTLMNATHRBTP53KDM4E | |
| SCHEMBL20768139 | 0.88 | KDM4E (0.39) | MAPTLMNATHRBTP53KDM4E | |
| SCHEMBL22280894 | 0.87 | KDM4E (0.57) | MAPTLMNATHRBTP53KDM4E | |
| SCHEMBL19492666 | 0.86 | MAPT (0.38) | MAPTLMNATHRBTP53KDM4E | |
| SCHEMBL24455511 | 0.83 | MAPT (0.42) | MAPTLMNATHRBTP53KDM4E | |
| SCHEMBL19463509 | 0.83 | TP53 (0.49) | MAPTLMNATHRBTP53KDM4E | |
| SCHEMBL28623625 | 0.81 | MAPT (0.34) | MAPTLMNATP53KDM4EALDH1A1 | |
| SCHEMBL19464076 | 0.78 | ALDH1A1 (0.47) | MAPTLMNATP53KDM4EALDH1A1 | |
| SCHEMBL19464265 | 0.78 | KDM4E (0.49) | MAPTLMNATP53KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001590-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-07-30 | — | — | US | disclosed |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001590-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | MAPT 4495/4885LMNA 2619/4885THRB 3961/4885 |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | MAPT 4497/4885LMNA 2671/4885THRB 3967/4885 |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | MAPT 4495/4885LMNA 2619/4885THRB 3961/4885 |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | MAPT 4495/4885LMNA 2619/4885THRB 3961/4885 |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | MAPT 4346/4885LMNA 3036/4885THRB 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.